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 Given the upcoming 2011 bundling of 
payments for separately reimbursable 
drugs such as erythropoiesis-stimulating 
agents (ESAs) and intravenous (IV) iron 
into the dialysis payment in the United 
States, the report by Hasegawa  et al. 1 (this 
issue) of Japan ’ s experience with anemia 
management practices following a similar 
reimbursement change is particularly 
timely and relevant. Although the major 
driving force for reimbursement bundling 
in the United States was the cost of ESAs, 
which constitute 10 % of Medicare costs 
for end-stage renal disease (ESRD) 
patients, it is interesting to note that Japa-
nese policymakers identifi ed a similar 
economic imperative despite that ESAs 
constituted only 6 % of total costs for 
ESRD treatment and that reimbursement 
for ESAs for ESRD patients is capped at 
9000 units per week in Japan as opposed 
to 400,000 units per month in the United 
States. Nonetheless, the change in Japa-
nese reimbursement policy appears to 
have had its desired eff ect of decreasing 
ESA use while maintaining constant 
hemoglobin (Hb) levels, largely associ-
ated with an increase in IV iron use. It is 
anticipated that a similar scenario will 
occur in the United States aft er January 
2011, although in the United States there 
is also a secular trend of decreasing ESA 
doses 2 and Hb levels, 3 which began aft er 
the publication of the Correction of 
Hemoglobin and Outcomes in Renal 
Insuffi  ciency (CHOIR) study 4 in 2006 
and was sustained by changes in ESA 
reimbursement policy in 2008. A secular 
trend of increased IV iron use in the 
United States since 2006 has not yet been 
identifi ed, because of the discontinuation 
of the ESRD Clinical Performance Meas-
ures Project, which previously collected 
such data, and the lag time for claims data 
reported in the US Renal Data System 
Annual Data Report. 
 Following the publication of the CHOIR 
study 4 in 2006, which demonstrated 
increased mortality among patients treated 
with ESAs to higher target Hb levels, Con-
gress began to apply pressure on Medicare 
to implement a bundled payment system 
for dialysis, and a timeline was established 
in the Medicare Improvements for Patients 
and Providers Act (MIPPA) of 2008. In 
September 2009, a proposed rule was 
released by the Centers for Medicare and 
Medicaid Services, which was fi nalized in 
July 2010 for implementation in January 
2011. MIPPA mandated a 2 % decrease in 
overall expenditures for the ESRD pro-
gram with the onset of bundled payment 
(as opposed to the targeted reduction of 
4 % in Japan) but did not specify how that 
reduction would occur at the provider 
level. It has been argued that the cost sav-
ings of ESAs in a bundled payment envi-
ronment could be as high as 50 % and that 
these savings should be passed on to Medi-
care through greater reductions in pay-
ment to facilities. 5 Th is would be achieved 
by conversion to subcutaneous (SC) ESA 
administration, more aggressive IV iron 
use, 6 lowering of Hb targets within the 
range of 10 – 12  g / dl, and more conservative 
use of ESAs in resistant patients. 7 
 Despite considerable evidence regard-
ing the potential ESA dose and cost sav-
ings of SC versus IV ESA administration, 8 
providers in Japan continued to adminis-
ter ESAs IV in a bundled payment envi-
ronment, largely because of concerns 
regarding pure red cell aplasia (PRCA). 
Whether this will be the case in the United 
States remains to be seen. PRCA is 
extremely rare in the United States, per-
haps because of consistency of the manu-
facturing process from a single vendor. 
Nephrologists in the United States typi-
cally administer ESAs SC to anemic 
patients with chronic kidney disease who 
are not on dialysis (CKD-ND) and those 
receiving peritoneal dialysis (CKD-PD), 
so the SC route of administration is clearly 
acceptable. Th e National Kidney Founda-
tion Kidney Disease Outcomes Quality 
Initiative (KDOQI) guidelines for anemia 
management in patients with kidney dis-
ease recommend IV ESA administration 
for patients on hemodialysis and SC 
administration for CKD-ND and CKD-
PD patients; 9 this double standard would 
make it appear that PRCA is not truly a 
concern and that the major goal is to avoid 
the sting of SC administration in patients 
receiving hemodialysis who have an alter-
nate route of ESA administration readily 
available. Th e role of patient comfort and 
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satisfaction in US dialysis facilities has 
been emphasized by the Medicare require-
ment that providers administer and 
respond to patient quality-of-life and 
experience-of-care instruments on an 
annual basis. Th e push-back by patients 
that may occur, as well as a potential mar-
keting disadvantage, if ESA administra-
tion is switched from the IV to the SC 
route may be enough to give US providers 
pause in making this change in 2011. 
 Most of the larger dialysis providers in 
the United States are already preparing 
for the bundled payment system by test-
ing ESA and iron protocols to determine 
which are the most cost-eff ective. Th e 
ability of a provider to achieve consistent 
Hb levels will be paramount, not only for 
patient safety (avoiding high Hb levels) 
and quality of life (avoiding low Hb levels), 
but also to maximize reimbursement, as 
Medicare will reward providers fi nan-
cially for keeping patients ’ Hb levels 
within the 10- to 12-g / dl range starting in 
2012. More consistent application of ane-
mia management algorithms and delega-
tion of protocol-driven ESA and IV iron 
dose titration to an  ‘ anemia management 
nurse ’ within a dialysis facility may be 
responsible for the decrease in the Hb 
standard deviation from 1.49 to 1.35  g / dl 
between 2006 and 2008. 3 It is likely that 
such anemia management algorithms will 
cap the ESA dose well below the 400,000 
units per month currently reimbursed by 
Medicare, both to decrease costs and to 
respond to concerns that such high doses 
may be associated with adverse patient 
outcomes. 10 Whether studies raising the 
latter concern are confounded by indica-
tion bias remains controversial, but recent 
actions by the US Food and Drug Admin-
istration to better inform patients regard-
ing the risks of ESA therapy will certainly 
contribute to a more ESA-conservative 
culture. It is likely that many patients pre-
viously receiving large doses of ESAs to 
maintain Hb levels in the 10- to 12-g / dl 
range will experience a decline in Hb to 
less than 10 g / dl as ESA doses are cur-
tailed. However, it is unclear whether this 
will lead to poorer outcomes, as the 
risk interplay of Hb level and ESA dose 
has yet to be fully elucidated. Some 
patients may be better off  with lower Hb 
doses and Hb levels less than 10  g / dl. 
If that proves to be the case, Medicare 
must reevaluate its anemia payment 
incentive program to adjust for case 
mix in such patients. 
 Under bundling, Japan achieved most of 
its ESA dose reduction through increased 
iron dosing. 1 Japan was and continues to be 
very conservative regarding IV iron therapy 
because of the higher incidence of hepatitis 
C and the long dialysis vintage in that coun-
try. IV iron is administered on an as-needed 
intermittent basis when transferrin satura-
tion is less than 20 % or serum ferritin less 
than 100  ng / ml. Unlike in the United States, 
maintenance IV iron protocols are discour-
aged. In the United States there has recently 
been a tendency to liberalize IV iron admin-
istration as an ESA-sparing strategy, espe-
cially since the publication of the Dialysis 
Patients ’ Response to IV Iron with Elevated 
Ferritin (DRIVE) study and its subsequent 
analyses. 6 Many US dialysis facilities con-
tinue to use a maintenance IV iron protocol 
of 50 – 100  mg / wk for patients with transfer-
rin saturation less than 50 % and serum fer-
ritin less than 800 – 1200  ng / dl, and some 
are administering additional doses of IV 
iron to maintain transferrin saturation 
between 30 and 50 % . Any additional oppor-
tunity for ESA dose and cost sparing with 
more aggressive IV iron management will 
probably occur in facilities that have 
historically been more conservative in 
their iron administration practices 
because of concerns regarding IV iron 
safety. Th e 2006 National Kidney Foun-
dation KDOQI anemia practice guide-
lines 9 provided modest guidance on this 
issue, and further studies are clearly 
needed to establish the optimal targets 
for IV iron therapy with respect to both 
short-term outcomes (Hb level and ESA 
dosing) and long-term outcomes (safety 
and mortality). 
 Although the economic drivers behind 
bundling of dialysis payment are the same 
in Japan and the United States, namely, cost 
savings primarily through reduction in 
ESA use, the options available to achieve 
that goal are somewhat diff erent. Japan 
succeeded through an increase in IV iron 
use, although still very conservative in 
comparison with doses used in the United 
States. SC ESA administration was not an 
option, because of concerns regarding 
PRCA, and as the weekly ESA dose was 
already capped at 9000 units by Japanese 
reimbursement policy, there was no oppor-
tunity to reduce ESA doses in very high 
users of the drug. In the United States there 
is already a secular trend toward decreased 
ESA use based on concerns regarding the 
safety of high ESA doses and Hb levels, 
reimbursement policies, and evidence 
 Figure 1  |  A conceptual model of the interplay among ESA and IV iron doses, costs, Hb level, 
and outcomes. The intersection between the ESA and iron cylinders represents the ESA-sparing 
effect of IV iron. Changing the doses of these drugs changes the size of the cylinders in all dimensions. 
The height of the cylinders corresponds to costs. The size of the footprint of the cylinders on the 
horizontal plane correlates with Hb level and potential toxic effects of the drugs, which may affect 
patient outcomes. The cylinders can move on the horizontal plane depending on the level of ESA 
resistance. In patients with more ESA resistance (low Hb levels despite high ESA doses), the cylinders 
move forward and to the left. ESA, erythropoiesis-stimulating agent; Hb, hemoglobin; IV, intravenous. 
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supporting more aggressive IV iron use as 
being safe and eff ective. Th is will no doubt 
accelerate under a bundled payment sys-
tem, but it is extremely unlikely that ESA 
use will decline by the 25 – 50 % predicted 
by some observers. 5 Although PRCA is not 
as much a concern in the United States as 
in Japan, it is not likely there will be a mas-
sive shift  to SC ESA administration under 
a bundled payment system; the overall 
decrease in ESA dose is likely to be similar 
to that in Japan, in the 10 – 20 % range. It will 
take many years for Medicare and other 
analysts to determine whether dialysis 
patients in the United States are better off  
with the lower ESA and higher IV iron 
doses that will inevitably result from eff orts 
at cost conservation. Th e interplay among 
ESA dosing, iron dosing, Hb achieved, cost 
containment, and long-term outcomes 
(survival) is extremely complex and will 
require sophisticated models to elucidate 
( Figure 1 ). It is hoped that the Centers for 
Medicare and Medicaid Services and the 
National Institutes of Health will exploit 
this unique opportunity to perform a struc-
tured analysis of the eff ects of this radical 
change in dialysis reimbursement on ane-
mia management processes and outcomes 
to inform policy makers and providers as 
US health care attempts to transition to a 
culture of comparative eff ectiveness. 
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 Fueling the fire in acute 
kidney injury: endothelial 
cells collect their Toll 
 Timothy A.  Sutton 1 and  Pierre C.  Dagher 1 
 Chen  et al. demonstrate endothelial expression of Toll-like receptor 4 
(TLR4) in the outer medulla of the kidney early in the course of ischemic 
acute kidney injury. Furthermore, they provide data that support the 
hypothesis that activation of endothelial TLR4 in the early extension 
phase of AKI by damage-associated molecular pattern molecules 
released from injured tubules results in endothelial activation. This 
activation can serve to amplify inflammation and tubular damage. 
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 Th ere is a long-standing appreciation that 
altered vascular function contributes to 
decreasing glomerular fi ltration rate dur-
ing acute kidney injury (AKI). Although 
overall renal blood fl ow is only transiently 
diminished following an inciting insult to 
the kidney, there is a more persistent and 
profound (relative to the cortex) decrease 
in outer medullary blood flow that is 
implicitly linked to the complex interplay 
among tubular injury, infl ammation, and 
endothelial alteration. 1 Th is interplay not 
only serves to adversely impact glomeru-
lar fi ltration rate but can also promote 
further tubular-cell injury beyond the 
 initial insult by extending tissue hypoper-
fusion. Activation of infl ammation is an 
important component of both the initia-
tion and the extension of injury in 
ischemic AKI, and enhancement of leu-
kocyte – endothelial interactions is a sali-
ent feature of this process. Interruption of 
the leukocyte – endothelial interaction has 
been an attractive target for therapeutic 
intervention; however, the mechanisms 
of endothelial activation in AKI are 
poorly defi ned. Chen  et al. 2 (this issue) 
shed light on this area by providing evi-
dence that incriminates endothelial Toll-
like receptor 4 (TLR4) in the initiation of 
endothelial-cell activation and further 
implicates the innate immune system 
( Figure 1 ) in the pathophysiology of 
ischemic AKI. 3 
 Th e recognition of TLR4 as the receptor 
for endotoxin more than a decade ago 
revolutionized the fi elds of innate immu-
nity and infectious diseases. TLR4 is one 
of more than a dozen receptors belonging 
